PET Imaging to Predict Tumor Response
The following story originally appeared in the June 14, 2017, edition of the VUMC Reporter.
About 10 percent of patients with colorectal cancer express a mutated form of the signaling molecule BRAF, which may be targeted for treatment by selective BRAF inhibitors. PET (positron emission tomography) imaging using a standard glucose probe is not able to predict response to BRAF inhibitors.